20 Times Volume Spurt Alert: Hyderabad-based pharma penny stock under Rs 50, jumps 16.9% on September 11

DSIJ Intelligence-1 / 11 Sep 2025/ Categories: Penny Stocks, Trending

20 Times Volume Spurt Alert: Hyderabad-based pharma penny stock under Rs 50, jumps 16.9% on September 11

From Rs 30.51 per share (52-week low) to Rs 36.85 per share, the stock is up over 20 per cent.

Today, shares of Sigachi Industries Ltd jumped 16.9 per cent to Rs 36.85 per share from its previous closing of Rs 31.52 per share. The company has a market cap of over Rs 1,500 crore and has delivered good profit growth of 28 per cent CAGR over the last 5 years. From Rs 30.51 per share (52-week low) to Rs 36.85 per share, the stock is up over 20 per cent. The shares of the company saw a spurt in volume by more than 20 times.

Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.

DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.

The company opened an R&D Centre in Hyderabad on July 28, 2025, to boost its scientific capabilities. The centre will focus on developing high-value Active Pharmaceutical Ingredients (APIs) for global markets. A team of 32-35 scientists will manage the entire API development process, from initial research to commercialisation and regulatory filings. The new facility will help Sigachi expedite product development for regulated markets, targeting key therapeutic areas and enhancing its competitive edge.

According to Quarterly Results, the company reported net sales of Rs 128 crore and net loss of Rs 101 crore. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24.

Disclaimer: The article is for informational purposes only and not investment advice.